ECSP066378A - "un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo" - Google Patents
"un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo"Info
- Publication number
- ECSP066378A ECSP066378A EC2006006378A ECSP066378A ECSP066378A EC SP066378 A ECSP066378 A EC SP066378A EC 2006006378 A EC2006006378 A EC 2006006378A EC SP066378 A ECSP066378 A EC SP066378A EC SP066378 A ECSP066378 A EC SP066378A
- Authority
- EC
- Ecuador
- Prior art keywords
- apotosis
- therapeutic composition
- prepare
- procedure
- same
- Prior art date
Links
- 102000011727 Caspases Human genes 0.000 title abstract 2
- 108010076667 Caspases Proteins 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000002547 isoxazolines Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a un derivado de isoxazolina como un inhibidor contra varias caspasas, a un procedimiento para preparar el mismo y a una composición terapéutica para prevenir la inflamación y la apoptosis que comprende al mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20030059451 | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066378A true ECSP066378A (es) | 2006-08-30 |
Family
ID=36102769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006378A ECSP066378A (es) | 2003-08-27 | 2006-02-15 | "un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composicion terapeutica para prevenir la inflamacion y la apotosis que comprende el mismo" |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7557133B2 (es) |
| EP (1) | EP1660464B1 (es) |
| JP (1) | JP4503017B2 (es) |
| KR (1) | KR100594544B1 (es) |
| CN (1) | CN1842521B (es) |
| AP (1) | AP2104A (es) |
| AR (1) | AR045503A1 (es) |
| BR (1) | BRPI0413848B8 (es) |
| CA (1) | CA2535711C (es) |
| EA (1) | EA012080B1 (es) |
| EC (1) | ECSP066378A (es) |
| EG (1) | EG25751A (es) |
| IL (1) | IL173638A (es) |
| MA (1) | MA27999A1 (es) |
| MX (1) | MXPA06002267A (es) |
| MY (1) | MY162110A (es) |
| NO (1) | NO335620B1 (es) |
| NZ (1) | NZ545216A (es) |
| OA (1) | OA13244A (es) |
| PE (1) | PE20050371A1 (es) |
| TR (1) | TR200600899T2 (es) |
| TW (1) | TWI346110B (es) |
| UA (1) | UA83240C2 (es) |
| UY (1) | UY28494A1 (es) |
| WO (1) | WO2005021516A1 (es) |
| ZA (1) | ZA200601586B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100774999B1 (ko) * | 2005-02-26 | 2007-11-09 | 주식회사 엘지생명과학 | 이소옥사졸린 유도체 및 그의 제조 방법 |
| US7754909B1 (en) * | 2005-04-06 | 2010-07-13 | The Florida State University Research Foundation, Inc. | Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis |
| KR101299720B1 (ko) * | 2006-08-16 | 2013-08-28 | 주식회사 엘지생명과학 | 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법 |
| KR20080042290A (ko) * | 2006-11-09 | 2008-05-15 | 주식회사 엘지생명과학 | 피리돈 구조를 포함하는 캐스파제 저해제 |
| WO2009022746A1 (ja) | 2007-08-10 | 2009-02-19 | Nippon Soda Co., Ltd. | 含窒素複素環化合物および有害生物防除剤 |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| DK2288615T3 (en) | 2008-05-21 | 2017-09-04 | Genesis Tech Ltd | SELECTIVE CASPASE INHIBITORS AND APPLICATIONS THEREOF |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| AU2012234393B2 (en) | 2011-03-31 | 2017-02-02 | Bayer Cropscience Aktiengesellschaft | Herbicidally and fungicidally active 3-phenylisoxazoline-5-carboxamides and 3-phenylisoxazoline-5-thioamides |
| EP2697246B1 (en) | 2011-04-15 | 2018-03-07 | Genesis Technologies Limited | Selective cysteine protease inhibitors and uses thereof |
| US10104892B2 (en) | 2012-09-25 | 2018-10-23 | Bayer Cropscience Ag | Herbicidally and fungicidally active 3-heteroaryl-isoxazoline-5-carboxamides and 3-heteroaryl-isoxazoline-5-thioamides |
| EP2900645B1 (de) * | 2012-09-25 | 2019-08-21 | Bayer CropScience AG | Herbizid wirksame 3-phenylisoxazolinderivate |
| KR102040740B1 (ko) * | 2012-09-25 | 2019-11-05 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 제초 및 살진균성 5-옥시-치환된 3-페닐이속사졸린-5-카복사미드 및 5-옥시-치환된 3-페닐이속사졸린-5-티오아미드 |
| JP2017095353A (ja) * | 2014-03-27 | 2017-06-01 | 日本曹達株式会社 | イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤 |
| EP3142649B1 (en) | 2014-05-12 | 2019-07-24 | Conatus Pharmaceuticals, Inc. | Treatment of the complications of chronic liver disease with caspase inhibitor emricasan |
| CN105753853B (zh) | 2014-12-16 | 2020-08-04 | 沈阳中化农药化工研发有限公司 | 一种含异恶唑啉的脲嘧啶类化合物及其用途 |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| EP3397251A1 (en) | 2015-12-31 | 2018-11-07 | Conatus Pharmaceuticals, Inc. | Methods of using caspase inhibitors in treatment of liver disease |
| EP3522883A1 (en) | 2016-10-05 | 2019-08-14 | Novartis AG | Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
| JP7113831B2 (ja) * | 2017-01-23 | 2022-08-05 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | カスパーゼ阻害薬としての二環式化合物 |
| HUE056695T2 (hu) | 2017-06-13 | 2022-03-28 | Bayer Ag | Tetrahidro- és dihidrofurán-karbonsav-amidok gyomirtó 3-fenilizoxazolin-5-karboxamidjai |
| EP3638665B1 (de) | 2017-06-13 | 2021-07-21 | Bayer Aktiengesellschaft | Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von tetrahydro- und dihydrofurancarbonsäuren und -estern |
| US20200369630A1 (en) | 2017-08-17 | 2020-11-26 | Bayer Aktiengesellschaft | Herbicidally active 3-phenyl-5-trifluoromethylisoxazoline-5-carboxamides of cyclopentylcarboxylic acids and esters |
| JP7217751B2 (ja) | 2018-01-25 | 2023-02-03 | バイエル・アクチエンゲゼルシヤフト | 除草活性を示すシクロペンテニルカルボン酸誘導体の３－フェニルイソオキサゾリン－５－カルボキサミド類 |
| CA3133025A1 (en) | 2019-03-12 | 2020-09-17 | Bayer Aktiengesellschaft | Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters |
| ES2980695T3 (es) * | 2019-04-19 | 2024-10-02 | Lg Chemical Ltd | Profármaco de inhibidor de caspasas |
| JP7442914B2 (ja) * | 2019-04-30 | 2024-03-05 | エルジー・ケム・リミテッド | カスパーゼ阻害剤のプロドラッグ |
| KR102366226B1 (ko) * | 2019-05-31 | 2022-02-22 | 주식회사 엘지화학 | 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법 |
| TWI906428B (zh) | 2020-12-10 | 2025-12-01 | 南韓商Ｌｇ化學股份有限公司 | 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
| CN114908028B (zh) * | 2022-04-19 | 2024-05-31 | 杭州师范大学 | 一种双相体系下化学酶法级联催化腈类化合物的一锅法合成工艺 |
| WO2026064271A1 (en) | 2024-09-23 | 2026-03-26 | Fmc Corporation | Substituted bicyclic amide derivatives as herbicides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2738486B2 (ja) | 1992-11-20 | 1998-04-08 | ファイザー製薬株式会社 | 抗炎症剤としての新規なイソオキサゾリン類 |
| EP0730587B1 (en) * | 1993-11-26 | 1999-12-08 | Pfizer Inc. | 3-phenyl-2-isoxazolines as antiinflammatory agents |
| ATE154932T1 (de) * | 1993-11-26 | 1997-07-15 | Pfizer | Isoxazolinverbindungen als entzündungshemmende mittel |
| US5710159A (en) * | 1996-05-09 | 1998-01-20 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| KR100373375B1 (ko) * | 1998-04-03 | 2003-06-12 | 주식회사 엘지생명과학 | 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제 |
| WO2001021599A1 (en) * | 1999-09-17 | 2001-03-29 | Lg Chemical Ltd. | Caspase inhibitor |
| CN1137888C (zh) * | 1999-09-17 | 2004-02-11 | 株式会社Lgci | 半胱氨酰天冬氨酸蛋白酶抑制剂 |
-
2004
- 2004-08-24 KR KR1020040066726A patent/KR100594544B1/ko not_active Expired - Lifetime
- 2004-08-26 NZ NZ545216A patent/NZ545216A/en not_active IP Right Cessation
- 2004-08-26 AP AP2006003509A patent/AP2104A/en active
- 2004-08-26 MY MYPI20043481A patent/MY162110A/en unknown
- 2004-08-26 UA UAA200602050A patent/UA83240C2/ru unknown
- 2004-08-26 WO PCT/KR2004/002139 patent/WO2005021516A1/en not_active Ceased
- 2004-08-26 EP EP04774400.8A patent/EP1660464B1/en not_active Expired - Lifetime
- 2004-08-26 OA OA1200600061A patent/OA13244A/en unknown
- 2004-08-26 CA CA2535711A patent/CA2535711C/en not_active Expired - Lifetime
- 2004-08-26 US US10/568,503 patent/US7557133B2/en not_active Expired - Lifetime
- 2004-08-26 BR BRPI0413848A patent/BRPI0413848B8/pt not_active IP Right Cessation
- 2004-08-26 EG EG2004080370A patent/EG25751A/xx active
- 2004-08-26 TR TR2006/00899T patent/TR200600899T2/xx unknown
- 2004-08-26 AR ARP040103065A patent/AR045503A1/es active IP Right Grant
- 2004-08-26 JP JP2006524573A patent/JP4503017B2/ja not_active Expired - Lifetime
- 2004-08-26 TW TW093125466A patent/TWI346110B/zh not_active IP Right Cessation
- 2004-08-26 MX MXPA06002267A patent/MXPA06002267A/es active IP Right Grant
- 2004-08-26 CN CN2004800247028A patent/CN1842521B/zh not_active Expired - Lifetime
- 2004-08-26 EA EA200600465A patent/EA012080B1/ru not_active IP Right Cessation
- 2004-08-27 UY UY28494A patent/UY28494A1/es not_active IP Right Cessation
- 2004-08-27 PE PE2004000822A patent/PE20050371A1/es active IP Right Grant
-
2006
- 2006-02-09 IL IL173638A patent/IL173638A/en active IP Right Grant
- 2006-02-15 EC EC2006006378A patent/ECSP066378A/es unknown
- 2006-02-17 MA MA28820A patent/MA27999A1/fr unknown
- 2006-02-23 ZA ZA200601586A patent/ZA200601586B/en unknown
- 2006-03-24 NO NO20061362A patent/NO335620B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28494A1 (es) | Un derivado de isoxazolina como un inhibidor contra varias caspasas, un procedimiento para preparar el mismo y una composición terapeutica para prevenir la inflamación y la apoptosis que comprende el mismo. | |
| PA8554501A1 (es) | Composicion fungicida basada en derivados de arilamidina y compuestos fungicos conocidos | |
| UY28862A1 (es) | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
| AR045635A1 (es) | Empleo de agentes fungicidas par ala desinfeccion de semillas de cereales | |
| ECSP045429A (es) | Combinacion de compuestos organicos | |
| BRPI0410888A (pt) | uso de derivados de difenilmetano como inibidores de tirosinase | |
| UY27712A1 (es) | Indazoles sustituidos, composiciones que los contienen, procedimientos de fabricación y utilización | |
| DE602005019918D1 (de) | Formulierungen, die mitkroverkapselte etherische öle enthalten | |
| CR7877A (es) | Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor | |
| HN2008000792A (es) | Compuesto de cinamida biciclico | |
| MX2010005012A (es) | Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor. | |
| IN2015DN00502A (es) | ||
| AR052038A1 (es) | Composicion para el cuidado bucal que comprende un compuesto fenolico y vitaminas y derivados de vitaminas antioxidantes | |
| WO2007127333A3 (en) | Compositions for the treatment and prevention of eyelid swelling | |
| HN2003000063A (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades. | |
| CL2008001755A1 (es) | Metodo para reducir efectos de deterioro asociado con pesticidas, fertilizantes o una combinacion de los mismos en una planta que comprende el tratamiento con al menos un compuesto derivado de ciclopropeno. | |
| AR035293A1 (es) | Composicion oftalmica. | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| AR054939A1 (es) | Metodos para aplicar formulaciones antimicrobianas sobre alimentos | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| CR7608A (es) | Derivados de ciclotiocarbamativa como moduladores de rp y uso de los mismos para tratamiento de trastornos de la piel | |
| PA8584501A1 (es) | Nuevos derivados de oxazol | |
| PA8549401A1 (es) | Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido | |
| HN2003000104A (es) | Derivados de ciclopenteno | |
| PA8651401A1 (es) | Formas de dosificacion oral solidas que contienen una dosis baja de estradiol |